Why Pfizer Stock Crushed the Market on Monday
Investors flocked to (NYSE: PFE) stock on Monday following some highly encouraging news about one of the company's pipeline drugs. The holy grail of pharmaceutical companies and biotechs is the development of a medication with blockbuster potential, and Pfizer seems to have one on its hands. As a result, the company's shares rocketed more than 5% higher on Monday against an essentially flat S 500 index.
A peer-reviewed study of Pfizer's investigational drug danuglipron found that the medication lowered both blood sugar and body weight after 16 weeks of use when compared to a placebo. That study was published in the influential JAMA Network medical journal that morning.
On average, the phase 2 clinical trial's volunteers who were administered either 80- or 120-milligram doses of the drug twice per day lost roughly 10 pounds of weight across the 16 weeks.
Source Fool.com
Pfizer Inc. Aktie
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 28.42 € bedeuten.
